Item 8.01 Other Events.
On March 22, 2023, Tenax Therapeutics, Inc. (the "Company") issued a press
release announcing that the Company has been issued a patent by the United
States Patent and Trademark Office (USPTO) with claims covering the use of IV
levosimendan in the treatment of Pulmonary Hypertension associated with Heart
Failure with Preserved Ejection Fraction (PH-HFpEF). A copy of the press release
is attached hereto as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. Description
99.1 Press Release, dated as of March 22, 2023.
104 Cover Page Interactive Data File (embedded within the Inline XBRL
document).
2
© Edgar Online, source Glimpses